Reuters logo
BRIEF-The Medicines Company reports third-quarter 2017 business and financial results
October 25, 2017 / 11:18 AM / a month ago

BRIEF-The Medicines Company reports third-quarter 2017 business and financial results

Oct 25 (Reuters) - Medicines Co

* The Medicines Company reports third-quarter 2017 business and financial results

* Q3 GAAP loss per share $0.42 from continuing operations

* Q3 earnings per share view $-1.44 -- Thomson Reuters I/B/E/S

* Q3 adjusted non-GAAP loss per share $1.19 from continuing operations

* Says ‍operations worldwide net revenue was $16.9 million in Q3 of 2017 compared to $37.6 million in Q3 of 2016​

* Medicines Co - ‍continue to expect to announce a transaction to divest infectious disease business before end of year

* Medicines Co - ‍independent of ID business transaction, finalizing plans to significantly restructure remainder of Medicines Company​

* Medicines Co - ‍anticipate restructuring, intended to be substantially implemented in next 45 days, will reduce headcount to less than 60 people at Co

* Q3 revenue view $24.4 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below